MR-601

MR-601 is an investigational small molecule drug being developed by SHINKEI Therapeutics for the treatment of rare neurodegenerative diseases and epilepsy. Currently in the IND-enabling (preclinical) stage of development, the drug is part of a pipeline focused on Central Nervous System (CNS) disorders. SHINKEI Therapeutics utilizes a 505(b)(2) regulatory strategy, which suggests that MR-601 is likely a repurposed or reformulated version of an existing pharmaceutical product, optimized to address unmet needs in neurological conditions. While the specific active ingredient and biological target have not been publicly disclosed, the company's platform focuses on small molecule chemical drugs.